Latest News
Conference Coverage
‘Why did I choose this?’ Tackling burnout in oncology
Building a sustainable oncology workforce will not be easy, but improving staffing shortages and integrating resilience training can help, experts...
News
FDA OKs ivosidenib for IDH1-mutated myelodysplastic syndromes
For adults with a rare form of myelodysplastic syndromes, the FDA has approved a targeted therapy called ivosidenib.
Conference Coverage
Enfortumab vedotin/pembrolizumab hailed as new standard for upfront mUC
After decades of stagnation, an almost doubling of life expectancy has set a new bar for the first-line treatment of locally advanced/metastatic...
Conference Coverage
The sobering facts about alcohol and cancer
An ESMO session highlights the well-known links between alcohol consumption and cancer and calls on healthcare professionals to do more to raise...
Latest News
Study reveals potentially unnecessary CRC screening in older adults
“Personalized screening incorporating individual life expectancy may improve the value of screening.”
Conference Coverage
Enzalutamide improves metastasis-free survival, QoL in prostate cancer
“This is the first time we have seen this kind of results with a novel hormonal therapy without castration.”
Feature
Employment vs. private practice: Who’s happier?
“It used to be that fewer hospitals offered employment, so private practice was the way to go. Now, there are fewer privates because hospitals and...
Conference Coverage
Chemo-immunotherapy good, adding a PARP inhibitor better in endometrial cancer?
Dr. Tan noted, the AtTEnd data "continue to validate practice-changing therapy for dMMR endometrial cancer patients."
Latest News
Active surveillance preferred in low-risk prostate cancer
There was no difference in outcomes between treatment and active surveillance.
Conference Coverage
ALK inhibitor alectinib shows DFS benefit in early NSCLC
Interim findings from the ALINA trial show improved DFS with alectinib in the adjuvant setting vs. chemotherapy in resected stage IB-IIIA NSCLC....
Conference Coverage
Perioperative nivolumab improves EFS in resectable NSCLC
Interim findings from CheckMate 77T show an overall improvement in event-free survival with perioperative nivolumab vs. neoadjuvant nivolumab plus...